ChemicalBook >> CAS DataBase List >>Tamibarotene

Tamibarotene

CAS No.
94497-51-5
Chemical Name:
Tamibarotene
Synonyms
AM80;C12864;Amnoid;CS-1151;Amnolake;NSC 608000;amibarotene;Tamibarotene;UNII-08V52GZ;Retinoid AM 80
CBNumber:
CB7426841
Molecular Formula:
C22H25NO3
Molecular Weight:
351.44
MDL Number:
MFCD00866188
MOL File:
94497-51-5.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-04-21 17:10:26
Product description Number Pack Size Price
Tamibarotene ≥98% (HPLC) T3205 5mg $112
Tamibarotene ≥98% (HPLC) T3205 25mg $433
AM80 ≥98% 71770 5mg $81
AM80 ≥98% 71770 10mg $129
AM80 ≥98% 71770 25mg $298
More product size

Tamibarotene Properties

Melting point 231-232°C
Boiling point 449.6±45.0 °C(Predicted)
Density 1.154±0.06 g/cm3(Predicted)
RTECS DH6940000
storage temp. room temp
solubility Soluble to 50 mM in DMSO
pka 3.83±0.10(Predicted)
form powder
color white to off-white
InChI InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
InChIKey MUTNCGKQJGXKEM-UHFFFAOYSA-N
SMILES C(O)(=O)C1=CC=C(C(NC2=CC=C3C(=C2)C(C)(C)CCC3(C)C)=O)C=C1
FDA UNII 08V52GZ3H9
NCI Drug Dictionary tamibarotene
UNSPSC Code 12352200
NACRES NA.77

SAFETY

Risk and Safety Statements

WGK Germany  3
Storage Class 11 - Combustible Solids

Tamibarotene price More Price(35)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich T3205 Tamibarotene ≥98% (HPLC) 94497-51-5 5mg $112 2026-03-19 Buy
Sigma-Aldrich T3205 Tamibarotene ≥98% (HPLC) 94497-51-5 25mg $433 2026-03-19 Buy
Cayman Chemical 71770 AM80 ≥98% 94497-51-5 5mg $81 2024-03-01 Buy
Cayman Chemical 71770 AM80 ≥98% 94497-51-5 10mg $129 2024-03-01 Buy
Cayman Chemical 71770 AM80 ≥98% 94497-51-5 25mg $298 2024-03-01 Buy
Product number Packaging Price Buy
T3205 5mg $112 Buy
T3205 25mg $433 Buy
71770 5mg $81 Buy
71770 10mg $129 Buy
71770 25mg $298 Buy

Tamibarotene Chemical Properties,Uses,Production

Description

Tamibarotene (brand name: Amnolake) is a kind of orally administrated synthetic retinoid. It is used to overcome the all- trans retinoid acid (ATRA) resistance, having potential antineoplastic activity against the acute promyelocytic leukaemia (APL). It can also be used for the treatment of Alzheimer's disease, multiple myeloma and Crohn's disease. Tamibarotene takes effect through directly acting as the specific agonist for retinoid acid receptor alpha/beta, and potentially binding to the retinoid X receptors (RXR). Compared to the ATRA, Tamibarotene is chemically more stable and much more potent as an inducer of differentiation and apoptosis in promyelocytic leukemia cells.

References

https://en.wikipedia.org/wiki/Tamibarotene
https://www.drugbank.ca/drugs/DB04942

Description

AM80 is a retinoic acid receptor agonist that is selective for RARα (Kd = 62 nM; AC50 = 1.46 nM) compared to RARβ (Kd = 280 nM; AC50 = 6.87 nM) and RARγ (Kd = 816 nM; AC50 = 148.7 nM). It demonstrates greater specific binding to RARα compared to retinoic acid , which exhibits little selectivity across RARα, β, or γ. AM80 exhibits antiproliferative effects against acute promyelocytic leukemia cells, inducing human promyelocytic leukemia HL-60 cell differentiation with an ED50 value of 0.79 nM. It has also been shown to suppress the growth of other myeloid and lymphoid malignant cells.

Description

Tamibarotene, a selective agonist of the retinoic acid receptor, was launched in Japan as an oral treatment for relapsed or refractory acute promyelocytic leukemia (APL). APL is a form of acute myeloid leukemia (AML) characterized by a deficiency in mature blood cells and an excess of immature cells called promyelocytes in the bone marrow and peripheral blood. The current standard of care for APL includes treatment with all-trans-retinoic acid (ATRA), either alone or in combination with chemotherapy. ATRA is a high affinity ligand for two types of nuclear receptors, retinoic acid receptor (RAR) and retinoid X receptor (RXR), each of which has three subtypes (-α, -β, and -γ). Activation of RARα by ATRA causes promyelocytes to differentiate and mature, thereby inhibiting their proliferation and inducing disease remission. Although ATRA is one of the most clinically successful retinoids, its usage is hampered by the high rate of adverse effects, instability, and the appearance of ATRA-resistant leukemia cells.Adverse events included retinoic acid syndrome, hyperleukocytosis, xerosis, cheilitis, hypertriglyceridemia, and hypercholesterolemia; however, these side effects were generally milder than with ATRA, which all patients had received previously. Examination of human samples taken from Phase II and III clinical trials revealed that fecal excretion was the major elimination route, and the metabolism of tamibarotene occurred primarily through hydroxylation and taurine conjugation. In vitro, the plasma protein binding of tamibarotene is shown to be >98% in rats, dogs, and humans. Tamibarotene is synthesized from 5,5,8,8-tetramethyl-5,6,7, 8-tetrahydronaphthalene in a four-step sequence consisting of regioselective nitration in the 2-position, reduction of the nitro group by hydrogenation to produce the corresponding aniline derivative, acylation of the aniline intermediate with 4-(carbomethoxy)benzoyl chloride, and hydrolysis of the methyl ester.

Chemical Properties

Crystalline Solid

Originator

Toko Yakuhin Kogyo (Japan)

Uses

Tamibarotene, a retinoic acid receptor-α(RARα) agonist, was approved for the treatment of relapsed or refractory acute promyelocytic leukemia (APL) in Japan on June, 2005 and is currently marketed by Nippon Shinyaku Co. This novel drug has shown high remission rate among patients who have recurrent disease after all trans retinoic acid therapy.

Uses

Synthetic retinoic acid receptor-α/β-selective retinoid. Antineoplastic.

Uses

A RARα agonist that induces differentiation and apoptosis

Uses

Synthetic retinoic acid receptor-a/selective retinoid. Antineoplastic

Definition

ChEBI: A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine.

brand name

Amnolake

Biological Activity

Retinoic acid receptor α (RAR α ) agonist that induces differentiation (ED 50 = 0.79 nM) and apoptosis of HL-60 cells in vitro . Exhibits antiproliferative effects against a variety of human tumor cells lines (mean values of 35, 40 and 60% growth inhibition at 0.1, 1 and 10 μ M respectively) and displays anticancer activity against acute promyelocytic leukemia in vivo .

Biochem/physiol Actions

Tamibarotene (Am80) is a RAR α agonist. Tamibarotene was developed to overcome resistance to ATRA and is currently approved in Japan for treatment of recurrent acute promyelocytic leukemia (APL). The compound induces HL-60 cells differentiation and apoptosis. Similarly to TTNPB, the compound neither binds to nor transactivates the RXRs. In contrast to TTNPB (pan RAR agonist), Tamibarotene is rather specific toward RAR α. The compound is approximate 10 times more potent than ATRA.

Synthesis

Several synthesis of tamibarotene have been disclosed in the literature including the process scale synthesis as shown in the scheme. The synthesis started with preparation of dichloride 134 in 82% yield from diol 133 by treating with concentrated HCL in DCM. Friedal Crafts reaction of dichloride 134 with acetanilide in the presence of aluminum chloride at -15C for 2h provided acetanilide derivative 136 in 78% yield. In a single pot, the acetanilide was reacted with PCl5 and dimethylaniline at -25C for 1.5h followed by quenching the reaction with methanol for 2h after addition at -25C. Addition of dimethylaniline and terepthalic chloride mono-methylester at -30 - - 20C for 1 hr provided the tamibarotene methyl easter 137 in 81% yield. Hydrolysis of the ester by heating with sodium hydroxide in MeOH:water mixture for 1h followed isolation and crystallization gave tamibarotene (XIX) in 92% yield.

Synthesis_94497-51-5

storage

Store at RT

References

[1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[2] Patent: US5214202, 1993, A
[3] Letters in Drug Design and Discovery, 2016, vol. 13, # 8, p. 729 - 733
[4] Organic Process Research and Development, 2017, vol. 21, # 5, p. 748 - 753

94497-53-7
94497-51-5
Synthesis of Tamibarotene from Methyl 4-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl)benzoate

Tamibarotene Preparation Products And Raw materials

Global( 230)Suppliers
Supplier Tel Email Country ProdList Advantage
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21591 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 33024 60
career henan chemical co
+86-0371-86658258 +8613203830695 sales@coreychem.com China 29820 58
BOC Sciences
+1-631-485-4226 inquiry@bocsci.com United States 19552 58
Shanghai Standard Technology Co., Ltd.
18502101150 ft-sales@nature-standard.com CHINA 1923 58
Alchem Pharmtech,Inc.
8485655694 sales@alchempharmtech.com United States 63687 58
TopScience Biochemical
00852-68527855 info@itopbiochem.com China Hong Kong 902 58
career henan chemical co
+86-0371-86658258 +8613203830695 factory@coreychem.com China 29795 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-87569262 +86-15003564040 1056@dideu.com China 3982 58
SIMAGCHEM CORP
+86-5922680277 +86-13806087780 sale@simagchem.com China 17346 58

View Lastest Price from Tamibarotene manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Tamibarotene pictures 2026-04-21 Tamibarotene
94497-51-5
US $39.00-72.00 / mg 99.73% 10g TargetMol Chemicals Inc.
Tamibarotene pictures 2026-02-02 Tamibarotene
94497-51-5
US $0.00-0.00 / KG 5mg 99% 2000tons Shaanxi Dideu Medichem Co. Ltd
Tamibarotene pictures 2023-02-24 Tamibarotene
94497-51-5
US $0.00 / mg 20mg ≥98%(HPLC) 10 g Shanghai Standard Technology Co., Ltd.
  • Tamibarotene pictures
  • Tamibarotene
    94497-51-5
  • US $39.00-72.00 / mg
  • 99.73%
  • TargetMol Chemicals Inc.
  • Tamibarotene pictures
  • Tamibarotene
    94497-51-5
  • US $0.00-0.00 / KG
  • 99%
  • Shaanxi Dideu Medichem Co. Ltd
  • Tamibarotene pictures
  • Tamibarotene
    94497-51-5
  • US $0.00 / mg
  • ≥98%(HPLC)
  • Shanghai Standard Technology Co., Ltd.

Tamibarotene Spectrum

AM80 Tamibarotene 4-[(5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid 4-[[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic Acid Am 80 (pharmaceutical) Amnolake NSC 608000 Retinoid AM 80 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalene-2-ylaminocarbonyl)benzoic acid 4-[[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethylnaphthalen)-2-yl]aminocarbonyl]benzoic acid 4-[[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethylnaphthalen-2-yl)amino]carbonyl]benzoic acid C12864 4-[(5,5,8,8-tetraMethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbaMoyl]benzoic acid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetraMethyl-2-naphthalenyl)carbaMoyl]benzoic acid, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetraMethyl-2-naphthyl)carbaMoyl] benzoic acid TAMIBAROTENE,AM 80, AM-80, AM80 4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoicacid -((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid Amnoid N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl)-2-naphthyl)terephthalamic acid N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic acid UNII-08V52GZ Tamibarotene, >=99% Tamibarotene(Am-80) AM80; AM 80; AM-80 CS-1151 Benzoic acid, 4-[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]- Tamibarotene USP/EP/BP Butanoicacid,9-methoxy- amibarotene NSC 608000|||Am 80|||Amnolake Oteseconazole Impurity 5 AM 80, retinoic acid receptor alpha/beta (RAR alpha/beta) agonist Tamibarotene, 10 mM in DMSO 94497-51-5 Inhibitors Intermediates & Fine Chemicals Pharmaceuticals Retinoids